Anebulo Pharmaceuticals, (id:5709 ANEB)
1.46 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 12:56:51 PM)
Exchange closed, opens in 1 day 20 hours
-1.35 USD (-1.35%)
-4.58 USD (-4.58%)
-23.16 USD (-23.16%)
-29.47 USD (-29.47%)
-34.53 USD (-34.53%)
-80.48 USD (-80.48%)
About Anebulo Pharmaceuticals,
Market Capitalization 37.86M
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
| Headquarters (address) |
1017 Ranch Road 620 South Lakeway 78734 TX United States |
| Phone | 512 598 0931 |
| Website | https://www.anebulo.com |
| Employees | 2 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ANEB |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.25 - 3.30 |
| Market Capitalization | 37.86M |
| P/E trailing | -4.56 |
| P/E forward | -2.25 |
| Price/Book | 9.93 |
| Beta | -1.01 |
| EPS | -0.300 |
| EPS United States (ID:6, base:3399) | 24.27 |